IPSOGEN acquires from Personal Genome Diagnostics exclusive rights for new biomarkers - mutations of the IDH1 and IDH2 genes - which play a role in brain cancers, acute myelogenous leukemia (AML) and other malignancies.

Marseille, France, January 10, 2012 – IPSOGEN SA (Alternext: ALIPS), a majority-owned subsidiary of QIAGEN N.V. (Nasdaq: QGEN / Frankfurt, Prime Standard: QIA), today announced the acquisition of worldwide exclusive rights to testing for mutations of the IDH1 and IDH2 genes for diagnostic purposes from Personal Genome Diagnostics Inc, Baltimore, Maryland (PGDx).

IDH1 (isocitrate dehydrogenase 1) and IDH2 are enzymes. The mutations in IDH1 and IDH2 genes, discovered in 2008 by the founders of PGDx, are frequently found in brain cancers, including early-stage and late-stage gliomas. Subsequent studies have implicated IDH1/IDH2 mutations in AML and other cancers. The discovery of these mutations and of their prognostic role was a real breakthrough, as gliomas account for more than 80% of primary central nervous system malignancies, where there is an important medical need for more accurate prognostication.

“We are pleased to have the opportunity to develop assays for detection and measurement of this biomarkers that should generate supportive data for research and diagnosis into several cancers including Glioma and AML and that could also be valuable in the development of companion diagnostics”, explains Vincent Fert, CEO of IPSOGEN.

About IPSOGEN
IPSOGEN, “Cancer Profiler,” develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists’ decisions along their complex therapeutic path. With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with blood cancer, IPSOGEN is also targeting breast cancer. Its goal will be to provide diagnostic information that remained unavailable until now.

IPSOGEN is, since July 2011, a subsidiary of the QIAGEN group. As of June 30, 2011, IPSOGEN employed 75 people. Its headquarters are located in Marseille, France.
To find out more, visit www.ipsogen.com.

About PGDx
Personal Genome Diagnostics (PGDx) was launched in 2010 to bring next-generation genetic analyses to cancer patients. The founders of PGDx are international leaders in cancer genetics and were the first to perform genome-wide sequence analyses of human cancer. PGDx has developed proprietary methods to perform patient-specific analyses of the cancer genome using digital characterization technologies. PGDx currently offers comprehensive cancer genome analyses for personalized approaches to cancer medicine.
PGDx is located in the Science and Technology Park at Johns Hopkins in Baltimore, MD.
To find out more, visit www.personalgenome.com.
## Contacts

### IPSOGEN

**Vincent Fert**  
CEO  
Tel: + 33 (0)4 9129 3090  
fert@ipsogen.com

**Hélène Peyro-Saint-Paul, MD**  
CMO  
Tel: + 33 (0)4 9129 3090  
peyro-saint-paul@ipsogen.com

### ATCG Press

**Marielle Bricman**  
Tel: + 33 (0)4 9125 0785  
ipsogen@atcg-partners.com

### Personal Genome Diagnostics

**Luis Diaz, MD**  
CMO  
Tel: + 1 410 955 9997  
ldiaz@personalgenome.com

**Victor Velculescu, MD, PhD**  
CSO  
Tel: + 1 410 955 9997  
velculescu@personalgenome.com